MEDIANTECHNOLOGIES overview

Regulatory News: Median Technologies ( FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-based image analyses and imaging services for oncology drug developers, releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025. Fredrik Brag, Chief...

Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers, today announces the Company has agreed on a non-binding term sheet with the European Investment Bank (EIB) for a new loan facility for up to...

Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results: Publication Date 2024 results April 29, 2025* *Distribution after the close of trading About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image...

Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2024: 30,599 shares €134,615.99 in cash. Transactions during the second half 2024: BUY 253,462 shares 1,060,310.22 EUR 488 transactions SELL 259,038 shares 1,107,913.49 EUR 452 transactions For information, as of June 28 th , 2024, the...

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,516,983 Number of real voting rights* (excluding treasury shares**) 18,463,224 Theoretical number of voting rights* (including treasury shares**) 18,493,783 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of...

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,516,983 Number of real voting rights* (excluding treasury shares**) 18,457,997 Theoretical number of voting rights* (including treasury shares**) 18,493,783 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of...

Regulatory News: Median Technologies ( FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”) , a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) candidates for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers, today announced that it will attend the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, IL, USA,...

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,516,983 Number of real voting rights* (excluding treasury shares**) 18,452,795 Theoretical number of voting rights* (including treasury shares**) 18,493,783 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of...